More companies are unifying their global data, content, and processes across clinical operations with Veeva Vault CTMS. In less than a year, the number of Vault CTMS customers has doubled to 50, signaling the industry’s continued shift in adopting the advanced cloud application from Veeva Systems (NYSE:VEEV) to improve trial performance.
“CTMS is a highly complex area that has been held back for decades by a lack of innovation,” said Henry Galio, senior director for Veeva Vault CTMS. “Veeva Vault CTMS is meeting the industry’s significant need for a modern solution to streamline operations and conduct trials more efficiently and effectively.”
Vault CTMS provides organizations one complete source of trial information to make faster and smarter decisions throughout the course of a study. “Our prior CTMS was difficult to configure and use,” said Eric Hanson, IT Manager at SCRI. “Veeva Vault CTMS is a modern system that is easily configurable with advanced functionality, enabling us to increase study team engagement and improve report timeliness, all while eliminating manual processes.”
Vault CTMS is part of Veeva Vault Clinical Suite, the industry’s first suite of applications for EDC, coding, data management, CTMS, eTMF, and study start-up on a single cloud platform. Vault Clinical Suite helps companies eliminate system silos and unify clinical data management and clinical operations.
Learn more about Vault CTMS at the upcoming Veeva R&D Summit, Sept. 8-10, in Philadelphia, PA. The event is open to Veeva customers and invited guests. Register and view the agenda at veeva.com/R&DSummit.
For more on Veeva Vault CTMS, visit: veeva.com/CTMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 775 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2019 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.